Cargando…
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide var...
Autores principales: | Mottamal, Madhusoodanan, Zheng, Shilong, Huang, Tien L., Wang, Guangdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372801/ https://www.ncbi.nlm.nih.gov/pubmed/25738536 http://dx.doi.org/10.3390/molecules20033898 |
Ejemplares similares
-
Design, Synthesis, and Biological
Evaluation of Novel
Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
por: Zheng, Shilong, et al.
Publicado: (2014) -
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013) -
Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017) -
Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008) -
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)